Advanced drug delivery reviews最新文献

筛选
英文 中文
Integrated modeling of biomarkers, survival and safety in clinical oncology drug development 临床肿瘤药物开发中的生物标记物、生存和安全性综合建模
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-11-20 DOI: 10.1016/j.addr.2024.115476
Han Liu , Eman I.K. Ibrahim , Maddalena Centanni , Céline Sarr , Karthik Venkatakrishnan , Lena E. Friberg
{"title":"Integrated modeling of biomarkers, survival and safety in clinical oncology drug development","authors":"Han Liu ,&nbsp;Eman I.K. Ibrahim ,&nbsp;Maddalena Centanni ,&nbsp;Céline Sarr ,&nbsp;Karthik Venkatakrishnan ,&nbsp;Lena E. Friberg","doi":"10.1016/j.addr.2024.115476","DOIUrl":"10.1016/j.addr.2024.115476","url":null,"abstract":"<div><div>Model-based approaches, including population pharmacokinetic-pharmacodynamic modeling, have become an essential component in the clinical phases of oncology drug development. Over the past two decades, models have evolved to describe the temporal dynamics of biomarkers and tumor size, treatment-related adverse events, and their links to survival. Integrated models, defined here as models that incorporate at least two pharmacodynamic/ outcome variables, are applied to answer drug development questions through simulations, e.g., to support the exploration of alternative dosing strategies and study designs in subgroups of patients or other tumor indications. It is expected that these pharmacometric approaches will be expanded as regulatory authorities place further emphasis on early and individualized dosage optimization and inclusive patient-focused development strategies. This review provides an overview of integrated models in the literature, examples of the considerations that need to be made when applying these advanced pharmacometric approaches, and an outlook on the expected further expansion of model-informed drug development of anticancer drugs.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"216 ","pages":"Article 115476"},"PeriodicalIF":15.2,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chaotic (bio)printing in the context of drug delivery systems 药物输送系统中的混沌(生物)印刷
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-11-17 DOI: 10.1016/j.addr.2024.115475
Mario Moisés Alvarez , Ariel Cantoral-Sánchez , Grissel Trujillo-de Santiago
{"title":"Chaotic (bio)printing in the context of drug delivery systems","authors":"Mario Moisés Alvarez ,&nbsp;Ariel Cantoral-Sánchez ,&nbsp;Grissel Trujillo-de Santiago","doi":"10.1016/j.addr.2024.115475","DOIUrl":"10.1016/j.addr.2024.115475","url":null,"abstract":"<div><div>Chaotic (bio)printing, an innovative fabrication technique that uses chaotic flows to create highly ordered microstructures within materials, may be transformative for drug delivery systems. This review explores the principles underlying chaotic flows and their application in fabricating complex, multi-material constructs designed for advanced drug delivery and controlled release. Chaotic printing enables the precise layering of different active ingredients—a feature that may greatly facilitate the development of polypills with customizable release profiles. Recently, chaos-assisted fabrication has been extended to produce micro-architected hydrogel spheres in a high-throughput manner, potentially enhancing the versatility and efficiency of drug delivery methods. In addition, chaotic bioprinting enables the creation of evolved tissue models that more accurately emulate physiological systems, providing a more relevant platform for drug testing. This review also highlights the unique advantages of chaotic printing, including the ability to fabricate tissues with organized porosity and pre-vascularized structures, addressing critical challenges in tissue engineering. Despite its promising capabilities, challenges remain, particularly in expanding the range of materials compatible with chaotic printing. Continued research and development in this area are essential to fully realize the potential of chaotic (bio)printing in advancing drug delivery, paving the way for the next generation of smart drug delivery systems and functional tissue models for drug testing.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"216 ","pages":"Article 115475"},"PeriodicalIF":15.2,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142645836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic overview of strategies for photosensitizer and light delivery in antibacterial photodynamic therapy for lung infections 肺部感染抗菌光动力疗法中光敏剂和光传输策略的系统性概述
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-11-15 DOI: 10.1016/j.addr.2024.115472
Margarita O. Shleeva, Galina R. Demina, Alexander P. Savitsky
{"title":"A systematic overview of strategies for photosensitizer and light delivery in antibacterial photodynamic therapy for lung infections","authors":"Margarita O. Shleeva,&nbsp;Galina R. Demina,&nbsp;Alexander P. Savitsky","doi":"10.1016/j.addr.2024.115472","DOIUrl":"10.1016/j.addr.2024.115472","url":null,"abstract":"<div><div>Antimicrobial photodynamic therapy (aPDT) emerges as a viable treatment strategy for infections resistant to conventional antibiotics. A complex interplay of factors, including intracellular photosensitizer (PS) accumulation, photochemical reaction type, and oxygen levels, determines the efficacy of aPDT. Recent progress includes the development of modified PSs with enhanced lipophilicity and target-specific strategies to improve bacterial cell wall penetration and targeting. Nanotechnology-based approaches, such as using nanomaterials for targeted PS delivery, have shown promise in enhancing aPDT efficacy. Advancements in light delivery methods for aPDT, such as transillumination of large lesions and local light delivery using fiber optic techniques, are also being explored to optimize treatment efficacy in clinical settings. The limited number of animal models and clinical trials specifically designed to assess the efficacy of aPDT for lung infections highlights the need for further research in this critical area. The potential prospects of aPDT for lung tissue infections originating from antibiotic-resistant bacterial infections are also discussed in this review.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"215 ","pages":"Article 115472"},"PeriodicalIF":15.2,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delivery and kinetics of immersion optical clearing agents in tissues: Optical imaging from ex vivo to in vivo 浸泡式光学清除剂在组织中的输送和动力学:从体内到体外的光学成像
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-10-29 DOI: 10.1016/j.addr.2024.115470
Tingting Yu , Xiang Zhong , Dongyu Li , Jingtan Zhu , Valery V. Tuchin , Dan Zhu
{"title":"Delivery and kinetics of immersion optical clearing agents in tissues: Optical imaging from ex vivo to in vivo","authors":"Tingting Yu ,&nbsp;Xiang Zhong ,&nbsp;Dongyu Li ,&nbsp;Jingtan Zhu ,&nbsp;Valery V. Tuchin ,&nbsp;Dan Zhu","doi":"10.1016/j.addr.2024.115470","DOIUrl":"10.1016/j.addr.2024.115470","url":null,"abstract":"<div><div>Advanced optical imaging provides a powerful tool for the structural and functional analysis of tissues with high resolution and contrast, but the imaging performance decreases as light propagates deeper into the tissue. Tissue optical clearing technique demonstrates an innovative way to realize deep-tissue imaging and have emerged substantially in the last two decades. Here, we briefly reviewed the basic principles of tissue optical clearing techniques in the view of delivery strategies via either free diffusion or external forces-driven advection, and the commonly-used optical techniques for monitoring kinetics of clearing agents in tissue, as well as their <em>ex vivo</em> to <em>in vivo</em> applications in multiple biomedical research fields. With future efforts on the even distribution of both clearing agents and probes, excavation of more effective clearing agents, and automation of tissue clearing processes, tissue optical clearing should provide more insights into the fundamental questions in biological events clinical diagnostics.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"215 ","pages":"Article 115470"},"PeriodicalIF":15.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids 细胞外囊泡与脂质纳米颗粒在递送核酸方面的比较
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-10-28 DOI: 10.1016/j.addr.2024.115461
Johannes Bader, Finn Brigger, Jean-Christophe Leroux
{"title":"Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids","authors":"Johannes Bader,&nbsp;Finn Brigger,&nbsp;Jean-Christophe Leroux","doi":"10.1016/j.addr.2024.115461","DOIUrl":"10.1016/j.addr.2024.115461","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) are increasingly investigated for delivering nucleic acid (NA) therapeutics, leveraging their natural role in transporting NA and protein-based cargo in cell-to-cell signaling. Their synthetic counterparts, lipid nanoparticles (LNPs), have been developed over the past decades as NA carriers, culminating in the approval of several marketed formulations such as patisiran/Onpattro® and the mRNA-1273/BNT162 COVID-19 vaccines. The success of LNPs has sparked efforts to develop innovative technologies to target extrahepatic organs, and to deliver novel therapeutic modalities, such as tools for <em>in vivo</em> gene editing. Fueled by the recent advancements in both fields, this review aims to provide a comprehensive overview of the basic characteristics of EV and LNP-based NA delivery systems, from EV biogenesis to structural properties of LNPs. It addresses the primary challenges encountered in utilizing these nanocarriers from a drug formulation and delivery perspective. Additionally, biodistribution profiles, <em>in vitro</em> and <em>in vivo</em> transfection outcomes, as well as their status in clinical trials are compared. Overall, this review provides insights into promising research avenues and potential dead ends for EV and LNP-based NA delivery systems.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"215 ","pages":"Article 115461"},"PeriodicalIF":15.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress of tumor-resident intracellular bacteria for cancer therapy 将肿瘤驻留细胞内细菌用于癌症治疗的进展
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-10-09 DOI: 10.1016/j.addr.2024.115458
Peng Bao, Xian-Zheng Zhang
{"title":"Progress of tumor-resident intracellular bacteria for cancer therapy","authors":"Peng Bao,&nbsp;Xian-Zheng Zhang","doi":"10.1016/j.addr.2024.115458","DOIUrl":"10.1016/j.addr.2024.115458","url":null,"abstract":"<div><div>Emerging studies have disclosed the pivotal role of cancer-associated microbiota in supporting cancer development, progression and dissemination, with the in-depth comprehending of tumor microenvironment. In particular, certain invasive bacteria that hide in various cells within the tumor tissues can render assistance to tumor growth and invasion through intricate mechanisms implicated in multiple branches of cancer biology. Thus, tumor-resident intracellular microbes are anticipated as next-generation targets for oncotherapy. This review is intended to delve into these internalized bacteria-driven cancer-promoting mechanisms and explore diversified antimicrobial therapeutic strategies to counteract the detrimental impact caused by these intruders, thereby improving therapeutic benefit of antineoplastic therapy.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"214 ","pages":"Article 115458"},"PeriodicalIF":15.2,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142386048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current status and challenges of model-informed drug discovery and development in China 中国基于模型的药物研发现状与挑战
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-10-09 DOI: 10.1016/j.addr.2024.115459
Yuzhu Wang , Jia Ji , Ye Yao , Jing Nie , Fengbo Xie , Yehua Xie , Gailing Li
{"title":"Current status and challenges of model-informed drug discovery and development in China","authors":"Yuzhu Wang ,&nbsp;Jia Ji ,&nbsp;Ye Yao ,&nbsp;Jing Nie ,&nbsp;Fengbo Xie ,&nbsp;Yehua Xie ,&nbsp;Gailing Li","doi":"10.1016/j.addr.2024.115459","DOIUrl":"10.1016/j.addr.2024.115459","url":null,"abstract":"<div><div>In the past decade, biopharmaceutical research and development in China has been notably boosted by government policies, regulatory initiatives and increasing investments in life sciences. With regulatory agency acting as a strong driver, model-informed drug development (MIDD) is transitioning rapidly from an academic pursuit to a critical component of innovative drug discovery and development within the country. In this article, we provided a cross-sectional summary on the current status of MIDD implementations across early and late-stage drug development in China, illustrated by case examples. We also shared insights into regulatory policy development and decision-making. Various modeling and simulation approaches were presented across a range of applications. Furthermore, the challenges and opportunities of MIDD in China were discussed and compared with other regions where these practices have a more established history. Through this analysis, we highlighted the potential of MIDD to enhance drug development efficiency and effectiveness in China’s evolving pharmaceutical landscape.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"214 ","pages":"Article 115459"},"PeriodicalIF":15.2,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142386042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent applications of three-dimensional bioprinting in drug discovery and development 三维生物打印在药物研发中的最新应用。
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-09-19 DOI: 10.1016/j.addr.2024.115456
Kaixing Yang , Lingxin Wang , Sanjairaj Vijayavenkataraman , Yunong Yuan , Edwin C.K. Tan , Lifeng Kang
{"title":"Recent applications of three-dimensional bioprinting in drug discovery and development","authors":"Kaixing Yang ,&nbsp;Lingxin Wang ,&nbsp;Sanjairaj Vijayavenkataraman ,&nbsp;Yunong Yuan ,&nbsp;Edwin C.K. Tan ,&nbsp;Lifeng Kang","doi":"10.1016/j.addr.2024.115456","DOIUrl":"10.1016/j.addr.2024.115456","url":null,"abstract":"<div><div>The ability of three-dimensional (3D) bioprinting to fabricate biomimetic organ and disease models has been recognised to be promising for drug discovery and development as 3D bioprinted models can better mimic human physiology compared to two-dimensional (2D) cultures and animal models. This is useful for target selection where disease models can be studied to understand disease pathophysiology and identify disease-linked compounds. Lead identification and preclinical studies also benefit from 3D bioprinting as 3D bioprinted models can be utilised in high-throughput screening (HTS) systems and to produce efficacy and safety data that closely resembles clinical observations. Although no published applications of 3D bioprinting in clinical trials were found, there are two clinical trials planning to evaluate the predictive ability of 3D bioprinted models by comparing human and model responses to the same chemotherapy. Overall, this review provides a comprehensive summary of the latest applications of 3D bioprinting in drug discovery and development.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"214 ","pages":"Article 115456"},"PeriodicalIF":15.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142278761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA-loaded nanoparticles for the treatment of hematological cancers 用于治疗血液肿瘤的 RNA 载体纳米粒子
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-09-18 DOI: 10.1016/j.addr.2024.115448
Elisa Garbayo , Souhaila H. El Moukhtari , Carlos Rodríguez-Nogales , Xabier Agirre , Juan R. Rodriguez-Madoz , Paula Rodriguez-Marquez , Felipe Prósper , Patrick Couvreur , María J. Blanco-Prieto
{"title":"RNA-loaded nanoparticles for the treatment of hematological cancers","authors":"Elisa Garbayo ,&nbsp;Souhaila H. El Moukhtari ,&nbsp;Carlos Rodríguez-Nogales ,&nbsp;Xabier Agirre ,&nbsp;Juan R. Rodriguez-Madoz ,&nbsp;Paula Rodriguez-Marquez ,&nbsp;Felipe Prósper ,&nbsp;Patrick Couvreur ,&nbsp;María J. Blanco-Prieto","doi":"10.1016/j.addr.2024.115448","DOIUrl":"10.1016/j.addr.2024.115448","url":null,"abstract":"<div><p>Hematological cancers encompass a diverse group of malignancies affecting the blood, bone marrow, lymph nodes, and spleen. These disorders present unique challenges due to their complex etiology and varied clinical manifestations. Despite significant advancements in understanding and treating hematological malignancies, innovative therapeutic approaches are continually sought to enhance patient outcomes.</p><p>This review highlights the application of RNA nanoparticles (RNA-NPs) in the treatment of hematological cancers. We delve into detailed discussions on <em>in vitro</em> and preclinical studies involving RNA-NPs for adult patients, as well as the application of RNA-NPs in pediatric hematological cancer. The review also addresses ongoing clinical trials involving RNA-NPs and explores the emerging field of CAR-T therapy engineered by RNA-NPs. Finally, we discuss the challenges still faced in translating RNA-NP research to clinics.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"214 ","pages":"Article 115448"},"PeriodicalIF":15.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24002709/pdfft?md5=394e09e402e81b0f66099b1b06ffb9f2&pid=1-s2.0-S0169409X24002709-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142271869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome 打破最后的障碍:脂质纳米颗粒中阳离子和可电离脂质结构的演变,以逃离内质体。
IF 15.2 1区 医学
Advanced drug delivery reviews Pub Date : 2024-09-16 DOI: 10.1016/j.addr.2024.115446
Kaitlin Mrksich , Marshall S. Padilla , Michael J. Mitchell
{"title":"Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","authors":"Kaitlin Mrksich ,&nbsp;Marshall S. Padilla ,&nbsp;Michael J. Mitchell","doi":"10.1016/j.addr.2024.115446","DOIUrl":"10.1016/j.addr.2024.115446","url":null,"abstract":"<div><div>In the past decade, nucleic acid therapies have seen a boon in development and clinical translation largely due to advances in nanotechnology that have enabled their safe and targeted delivery. Nanoparticles can protect nucleic acids from degradation by serum enzymes and can facilitate entry into cells. Still, achieving endosomal escape to allow nucleic acids to enter the cytoplasm has remained a significant barrier, where less than 5% of nanoparticles within the <em>endo</em>-lysosomal pathway are able to transfer their cargo to the cytosol. Lipid-based drug delivery vehicles, particularly lipid nanoparticles (LNPs), have been optimized to achieve potent endosomal escape, and thus have been the vector of choice in the clinic as demonstrated by their utilization in the COVID-19 mRNA vaccines. The success of LNPs is in large part due to the rational design of lipids that can specifically overcome endosomal barriers. In this review, we chart the evolution of lipid structure from cationic lipids to ionizable lipids, focusing on structure–function relationships, with a focus on how they relate to endosomal escape. Additionally, we examine recent advancements in ionizable lipid structure as well as discuss the future of lipid design.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"214 ","pages":"Article 115446"},"PeriodicalIF":15.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142278760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信